Healthcare of Ontario Pension Plan Trust Fund Reduces Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Healthcare of Ontario Pension Plan Trust Fund trimmed its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 69.5% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 21,660 shares of the company’s stock after selling 49,340 shares during the period. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Neurocrine Biosciences were worth $2,987,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. First Horizon Advisors Inc. raised its stake in Neurocrine Biosciences by 10.5% during the 4th quarter. First Horizon Advisors Inc. now owns 782 shares of the company’s stock valued at $103,000 after buying an additional 74 shares during the last quarter. Quadrant Capital Group LLC lifted its holdings in Neurocrine Biosciences by 3.9% in the fourth quarter. Quadrant Capital Group LLC now owns 2,075 shares of the company’s stock valued at $273,000 after acquiring an additional 78 shares during the period. Envestnet Portfolio Solutions Inc. boosted its position in Neurocrine Biosciences by 3.2% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 2,530 shares of the company’s stock worth $333,000 after purchasing an additional 78 shares during the last quarter. Commonwealth Equity Services LLC grew its stake in shares of Neurocrine Biosciences by 0.6% during the 1st quarter. Commonwealth Equity Services LLC now owns 13,941 shares of the company’s stock valued at $1,923,000 after purchasing an additional 84 shares during the period. Finally, Balentine LLC increased its position in shares of Neurocrine Biosciences by 4.0% during the 4th quarter. Balentine LLC now owns 2,316 shares of the company’s stock valued at $305,000 after purchasing an additional 89 shares during the last quarter. Institutional investors own 92.59% of the company’s stock.

Insider Activity

In related news, insider Julie Cooke sold 900 shares of the business’s stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $150.04, for a total value of $135,036.00. Following the sale, the insider now owns 18,202 shares in the company, valued at $2,731,028.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Gary A. Lyons sold 930 shares of the company’s stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $150.03, for a total transaction of $139,527.90. Following the sale, the director now directly owns 119,047 shares in the company, valued at approximately $17,860,621.41. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Julie Cooke sold 900 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $150.04, for a total value of $135,036.00. Following the completion of the transaction, the insider now owns 18,202 shares of the company’s stock, valued at approximately $2,731,028.08. The disclosure for this sale can be found here. In the last ninety days, insiders sold 80,709 shares of company stock worth $11,009,150. 4.30% of the stock is currently owned by insiders.

Neurocrine Biosciences Stock Up 0.2 %

NBIX opened at $146.10 on Friday. The company has a market capitalization of $14.70 billion, a PE ratio of 40.25 and a beta of 0.37. The firm has a 50-day simple moving average of $139.07 and a two-hundred day simple moving average of $137.81. Neurocrine Biosciences, Inc. has a 52 week low of $99.36 and a 52 week high of $150.39.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Wednesday, May 1st. The company reported $0.42 EPS for the quarter, missing analysts’ consensus estimates of $1.04 by ($0.62). The firm had revenue of $515.30 million for the quarter, compared to the consensus estimate of $512.21 million. Neurocrine Biosciences had a net margin of 18.65% and a return on equity of 17.45%. As a group, sell-side analysts expect that Neurocrine Biosciences, Inc. will post 4.22 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. StockNews.com upgraded shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Friday, July 19th. Oppenheimer boosted their price objective on shares of Neurocrine Biosciences from $200.00 to $216.00 and gave the company an “outperform” rating in a research report on Thursday, May 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $155.00 target price on shares of Neurocrine Biosciences in a report on Thursday. Barclays boosted their price target on Neurocrine Biosciences from $150.00 to $169.00 and gave the company an “overweight” rating in a report on Thursday, May 2nd. Finally, Morgan Stanley raised their price objective on Neurocrine Biosciences from $160.00 to $170.00 and gave the stock an “overweight” rating in a research note on Friday, July 12th. Six investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $154.08.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.